Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2013 2
2014 3
2015 2
2016 2
2017 2
2018 3
2019 1
2020 1
2021 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A white raven detected by imaging.
Baur LH, Schreurs WM, van Leeuwen-Wintjes HR, Berendsen CL, Willems R, Winkens RA, Vliegen R, Theunissen P, Gomez Garcia EB. Baur LH, et al. Among authors: schreurs wm. Neth Heart J. 2015 Jul;23(7-8):402-4. doi: 10.1007/s12471-015-0706-5. Neth Heart J. 2015. PMID: 26031635 Free PMC article.
Surveillance of Clinically Complete Responders Using Serial 18F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
Valkema MJ, van der Wilk BJ, Eyck BM, Wijnhoven BPL, Spaander MCW, Doukas M, Lagarde SM, Schreurs WMJ, Roef MJ, van Lanschot JJB, Valkema R. Valkema MJ, et al. Among authors: schreurs wmj. J Nucl Med. 2021 Apr;62(4):486-492. doi: 10.2967/jnumed.120.247981. Epub 2020 Sep 4. J Nucl Med. 2021. PMID: 32887759 Free PMC article.
Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R. Valkema MJ, et al. Among authors: schreurs wmj. J Nucl Med. 2019 Nov;60(11):1553-1559. doi: 10.2967/jnumed.118.224196. Epub 2019 Mar 15. J Nucl Med. 2019. PMID: 30877177 Free article. Clinical Trial.
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P. Larue RT, et al. Among authors: schreurs wm. BMC Cancer. 2016 Aug 17;16:644. doi: 10.1186/s12885-016-2709-z. BMC Cancer. 2016. PMID: 27535748 Free PMC article. Clinical Trial.
17 results